Skip to main content
SpringerLink
Log in

Mortality Associated with Selegiline in Parkinson’s Disease

What Do the Available Data Mean?

  • Current Opinion
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

A recent study by the Parkinson’s Disease Research Group of the United Kingdom revealed higher mortality in patients with Parkinson’s disease who were treated with selegiline (deprenyl) compared with those who were not. In this article, the methodological limitations of the UK study are discussed.

Although several problems exist with this study, the mortality rate was correct, since the data were obtained from a verifiable source. The question then is whether or not the higher mortality rate can be ascribed to selegiline. It is difficult to find answers to this question in the study data, and we will have to wait for the study authors’ final report.

No other studies have reported higher mortality with selegiline. However, when prescribing selegiline in patients with early-stage Parkinson’s disease, it is important to provide them with all the available information so that treatment decisions can be made jointly. Meanwhile, the best indication for selegiline appears to be motor fluctuations in patients with moderately advanced Parkinson’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Demarest K, Smith D, Azzaro A. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons. J Pharmacol Exp Ther 1980; 215: 461–8

    PubMed  CAS  Google Scholar 

  2. Damier P, Kastner A, Agid Y, et al. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson’s disease? Neurology 1996; 46: 1262–9

    Article  PubMed  CAS  Google Scholar 

  3. Levitt P, Pintar J, Breakfield X. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 1982; 79: 6385–9

    Article  PubMed  CAS  Google Scholar 

  4. Chiba K, Trevor AJ, Castagnoli Jr N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem Biophys Res Commun 1984; 120: 574–8

    Article  PubMed  CAS  Google Scholar 

  5. Heikkila RE, Manzino L, Cabbat FS, et al. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984; 311: 467–9

    Article  PubMed  CAS  Google Scholar 

  6. Parkinson Study Group. Effect of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl JMed 1993; 328: 176–83

    Article  Google Scholar 

  7. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson’s disease in DATATOP subjects not requiring levodopa. Ann Neurol 1996; 39: 29–36

    Article  Google Scholar 

  8. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson’s disease. Ann Neurol 1995; 38: 771–7

    Article  PubMed  CAS  Google Scholar 

  9. Lees AJ. Parkinson’s Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson’s disease. BMJ 1995; 311: 1602–7

    Article  PubMed  CAS  Google Scholar 

  10. Parkinson’s Disease Research Group in the United Kingdom. Comparison of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson’s disease: three-year interim report. BMJ 1993; 307: 469–72

    Article  Google Scholar 

  11. Mäki-Ikola O, Kilkku O, Heinonen E. Effect of adding selegiline to levodopa in early, mild Parkinson’s disease. Other studies have not shown increased mortality [letter]. BMJ 1996; 312: 702

    PubMed  Google Scholar 

  12. Anderson KE, Girdwood AC, Wilson JA. Stopping selegiline may lead to problems for patients [letter]. BMJ 1996; 312: 702

    Article  PubMed  CAS  Google Scholar 

  13. Olanow CW, Goodbold JH, Koller W. Patients taking selegiline may have received more levodopa than necessary [letter]. BMJ 1996; 312: 702–3

    PubMed  CAS  Google Scholar 

  14. MacMahon DG, Bland R. Selegiline is effective and safe in early stages [letter]. BMJ 1996; 312: 703

    PubMed  CAS  Google Scholar 

  15. Silva MT, Watts PM, Jenner P. Parkinson’s disease is rarely a primary cause of death [letter]. BMJ 1996; 312: 703

    Article  PubMed  CAS  Google Scholar 

  16. Yu PH, Lai CT, Boulton AA. Selegiline may be toxic in presence of increased dopamine concentrations [letter]. BMJ 1996; 312: 703–4

    PubMed  CAS  Google Scholar 

  17. Gerlach M, Riederer P, Vogt H. ’On treatment’ rather than intention to treat analysis should have been used [letter). BMJ 1996; 312: 704

    PubMed  CAS  Google Scholar 

  18. Jellinger KA. Causes of death need confirmation [letter]. BMJ 1996; 312: 704

    Article  PubMed  CAS  Google Scholar 

  19. Mena MA, Pardo B, Casarejos MJ, et al. Neurotoxicity of levodopa on catecholamine-rich neurons. Mov Disorders 1992; 7: 23–31

    Article  CAS  Google Scholar 

  20. Spencer JPE, Jenner A, Aruoma OJ, et al. Intense oxidative DNA damage promoted by L-DOPA and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994; 353: 246–50

    Article  PubMed  CAS  Google Scholar 

  21. Tanaka M, Sotomatsu A, Kanai H, et al. Combined histochemical and biochemical demonstration of nigral vulnerability to lipid peroxidation induced by DOPA and iron. Neurosci Lett 1992: 140: 42–6

    Article  PubMed  CAS  Google Scholar 

  22. Hoehn MM. Parkinsonism treated with levodopa: progression and mortality. J Neural Transm 1983; Suppl. 19: 253–64

    Google Scholar 

  23. Diamond SG, Markham CH, Hoehn MM, et al. Multi-center study of Parkinson mortality with early versus later dopa treatment. Ann Neurol 1987; 22: 8–12

    Article  PubMed  CAS  Google Scholar 

  24. Scigliano G, Musicco M, Soliveri P, et al. Mortality associated with early and late levodopa therapy initiation in Parkinson’s disease. Neurology 1990; 40: 265–9

    Article  PubMed  CAS  Google Scholar 

  25. Mytilineou C, Han SK, Cohen G. Toxic and protective effects of L-DOPA on mesencephalic cell cultures. J Neurochem 1993; 61: 1470–8

    Article  PubMed  CAS  Google Scholar 

  26. Han SK, Mytilineou C, Cohen G. L-DOPA up-regulates glutathione and protects mesencephalic cultures against oxidative stress. J Neurochem 1996; 66: 501–10

    Article  PubMed  CAS  Google Scholar 

  27. Duarte J, Almuina JV, Sevillano MD, et al. Atrial fibrillation induced by selegiline. Parkinsonism Related Disord 1996; 2: 125–6

    Article  CAS  Google Scholar 

  28. Lees AJ, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson’s disease. Lancet 1977; II: 791–5

    Article  Google Scholar 

  29. Rinne UK, Siirtola T, Sonninen V. L-Deprenyl treatment of on-off phenomena in Parkinson’s disease. J Neural Transm 1978; 43: 253–62

    Article  PubMed  CAS  Google Scholar 

  30. Schachter M, Marsden CD, Parkes JD. Deprenyl in the management of response fluctuations in patients with Parkinson’s disease on levodopa. J Neurol Neurosurg Psychiatry 1980; 43: 1016–21

    Article  PubMed  CAS  Google Scholar 

  31. Brodersen P, Philbert A, Gulliksen G, et al. The effect of L-deprenyl on on-off phenomena in Parkinson’s disease. Acta Neurol Scand 1985; 71: 494–7

    Article  PubMed  CAS  Google Scholar 

  32. Golbe LI, Lieberman AN, Muenter MD, et al. Deprenyl in the treatment of symptom fluctuations in advanced Parkinson’s disease. Clin Neuropharmacol 1988; 11: 45–55

    Article  PubMed  CAS  Google Scholar 

  33. Golbe LI. Long-term efficacy and safety of deprenyl (selegiline) in advanced Parkinson’s disease. Neurology 1989; 39: 1109–11

    Article  PubMed  CAS  Google Scholar 

  34. Cedarbaum JM, Silvestri M, Clark M, et al. L-deprenyl, levodopa pharmacokinetics, and response fluctuations in Parkinson’s disease. Clin Neuropharmacol 1990; 13: 29–35

    Article  PubMed  CAS  Google Scholar 

  35. Myllylä VV, Sotaniemi KA, Vuorinen JA, et al. Selegiline in de nova parkinsonian patients: the Finnish study. Mov Disord 1993; 1: S41–4

    Article  Google Scholar 

  36. Tetrud JW, Langston JW. The effect of deprenyl (selegiline) on the natural history of Parkinson’s disease. Science 1989; 45: 519–22

    Article  Google Scholar 

  37. Allain H, Pollak P, Neukirch HC, et al. Symptomatic effect of selegiline in de nova parkinsonian patients. Mov Disord 1993; 8: S36–40

    Article  PubMed  Google Scholar 

  38. Teräväinen H. Selegiline in Parkinson’s disease. Acta Neurol Scand 1990; 81: 333–6

    Article  PubMed  Google Scholar 

  39. Brannan T, Yahr M. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson’s disease. Ann Neurol 1995; 37: 95–8

    Article  PubMed  CAS  Google Scholar 

  40. Rinne UK. Combination of a dopamine agonist, MAO-B inhibitor and levodopa: a new strategy in the treatment of early Parkinson’s disease. Acta Neurol Scand 1989; 126: 165–9

    Article  CAS  Google Scholar 

  41. Baronti F, Davis TL, Boldry RC, et al. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology 1992; 42: 541–4

    Article  PubMed  CAS  Google Scholar 

  42. Elizan TS, Yahr MD, Moros DA, et al. Selegiline as an adjunct to conventional levodopa therapy in Parkinson’s disease: experience with this type B monoamine oxidase inhibitor in 200 patients. Arch Neurol 1989; 48: 1280–3

    Article  Google Scholar 

  43. Yahr MD. [editorial]. Parkinsonism Related Disord 1996; 2: 123–4

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo, Tokyo 113, Japan

    Yoshikuni Mizuno & Tomoyoshi Kondo

Authors
  1. Yoshikuni Mizuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tomoyoshi Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mizuno, Y., Kondo, T. Mortality Associated with Selegiline in Parkinson’s Disease. Drug-Safety 16, 289–294 (1997). https://doi.org/10.2165/00002018-199716050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199716050-00001

Keywords

Search

Navigation